Background: One of the main objectives of dialysis is uremic retention product elimination. Efficiency of dialysis modalities varies both regarding the range of solutes removed and the extent of such removal. We analyzed plasma (or blood) concentrations of marker solutes in intermittent treatment schedules using hemodiafiltration (HDF). Methods: Elimination and rebound of uremic solutes were measured in 10 patients (77 ± 12 kg, 66.5 ± 9.2 years) treated with postdilution HDF in one 4-hour treatment and in two 2-hour treatments on consecutive days (Polyflux 2.1 m2, QB 451 ± 53 ml/min, QD 598 ± 13 ml/min). Blood urea, creatinine, phosphate, β2-microglobulin, complement factor D and advanced glycation end products were analyzed before, during and after HDF for 24-48 h. Results: Applying two 2-hour HDF treatments on consecutive days resulted in significantly lower plasma (or blood) levels of urea, creatinine, phosphate, β2-microglobulin, and advanced glycation end products after 48 h than using one 4-hour session. Conclusions: Increased treatment frequency could further optimize blood purification in HDF therapy.

Keywords:
Hemodiafiltration, Frequent dialysis, Solute clearance, Phosphate, Rebound
1.
Depner TA, Bhat A: Quantifying daily hemodialysis. Semin Dial 2004;17:79-84.
2.
Clark WR, Leypoldt JK, Henderson LW, et al: Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 1999;10:601-609.
3.
Maduell F, Arias M, Durán CE, Vera M, Fontseré N, Azqueta M, Rico N, Pérez N, Sentis A, Elena M, Rodriguez N, Arcal C, Bergadá E, Cases A, Bedini JL, Campistol JM: Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative. Nephrol Dial Transplant 2012;27:1619-1631.
4.
Oppermann M, Baumgarten H, Brandt E, et al: Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods 1990;133:181-190.
5.
Henle T, Deppisch R, Beck W, et al: Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
6.
Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Lévesque R, Nubé MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012;23:1087-1096.
7.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M; Turkish Online Haemodiafiltration Study: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013;28:192-202.
8.
Canaud B, Bragg-Gresham JL, Marshall MR, et al: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093.
9.
Jirka T, Cesare S, Di Benedetto A, Perera Chang M, Ponce P, Richards N, Tetta C, Vaslaky L: Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 2006;70:1524, author reply 1524-1525.
10.
Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K: Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009;4:1944-1953.
11.
Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, Ramírez R, Tetta C, Rodríguez M, Martín-Malo A, Aljama P: On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006;17:2315-2321.
12.
Maduell F, Navarro V, Torregrosa E, et al: Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003;64:305-313.
13.
Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK: Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis 2002;40:1211-1218.
14.
Blumenkrantz MJ, Kopple JD, Moran JK, et al: Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982;21:849-861.
15.
Ward RA, Schmidt B, Hullin J, et al: A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000;11:2344-2350.
16.
Cheung AK, Rocco MV, Yan G, et al: Serum {beta}-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study. J Am Soc Nephrol 2006;17:546-555.
17.
Floege J, Granolleras C, Deschodt G, et al: High-flux synthetic versus cellulosic membranes for beta 2-microglobulin removal during hemodialysis, hemodiafiltration and hemofiltration. Nephrol Dial Transplant 1989;4:653-657.
18.
Balke N, Holtkamp U, Horl WH, et al: Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. FEBS Lett 1995;371:300-302.
19.
Imani F, Horii Y, Suthanthiran M, et al: Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993;178:2165-2172.
20.
Haslbeck KM, Bierhaus A, Erwin S, et al: Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 2004;29:853-860.
21.
Santoro A, Canova C, Mancini E, Deppisch R, Beck W: Protein loss in on-line hemofiltration. Blood Purif 2004;22:261-268.
22.
Galland R, Traeger J, Arkouche W, et al: Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int 2001;60:1555-1560.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.